Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|September 14, 2019
Utility of the RIG-I Agonist Triphosphate RNA for Melanoma TherapyMike W Helms, Kerstin Jahn-Hofmann, Felix Gnerlich, et al.
Blood|February 24, 2022
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myelomaSahar Kassem, Béré K Diallo, Nizar El-Murr, et al.
Oncoimmunology|April 2, 2021
An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapyMarie Bernardo, Tatiana Tolstykh, Yu-An Zhang, et al.
Blood|July 10, 2014
PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogeneZhuyan Guo, Anlai Wang, Weidong Zhang, et al.
Plos One|August 25, 2020
An iron-dependent metabolic vulnerability underlies VPS34-dependence in RKO cancer cellsMarek J Kobylarz, Jonathan M Goodwin, Zhao B Kang, et al.
Nucleic Acids Research|January 1, 2015
Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cellsTimothy R Wagenaar, Tatiana Tolstykh, Chaomei Shi, et al.
Leukemia|February 12, 2025
Immunotherapy targeting a leader sequence cathepsin G-derived peptideChunhua Shi, Ze Tian, Jun Yan, et al.
Oncotarget|February 1, 2018
Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activationZhihu Ding, Chaomei Shi, Lan Jiang, et al.
The Journal of Biological Chemistry|September 5, 2013
Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approachesQiang Gao, Ingrid Mechin, Nayantara Kothari, et al.
Molecular Cancer Therapeutics|February 13, 2023
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in TumorsBen Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith, et al.
Pageof 4